ELN segregated CN-AML patients based on presence of FLT3-ITD, mutations of NPM1 and CEBPA. After adjusting for the impact of these known risk factors, we performed multivariable analyses to confirm the prognostic significance of RUNX1 expression. This evidence concerns the gene NPM1 and acute myeloid leukemia.